RxDoctor Payments Data

Christopher Dermarkarian, MD

Ophthalmic Plastic and Reconstructive Surgery · Durham, NCNPI 1093246076

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Amgen at 31.5% of the total.

$2,459in general payments, 2019–2025

Across 30 payments — averaging $81.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$775
  • Alcon$462
  • Merz Pharmaceuticals, LLC$274
  • Alcon Research LLC$215
  • Biotissue Holdings Inc.$199
  • Glaukos Corporation$157
  • plus $376 from 5 others
$2,285in research payments, 2019–2025

Across 16 payments — averaging $142.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Argenx US, Inc.$2K

What the payments were for

  • Food & beverage$2,459100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few ophthalmic plastic and reconstructive surgery providers in North Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$164,958
Medicare patients
255
Services billed
2,366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErythromycinErythromycin Base154$1,797
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha56$616
Doxycycline Hyclate35$376
Bacitracin-PolymyxinBacitracin/Polymyxin B Sulfate22$260
Ofloxacin22$227
Cephalexin34$167
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen15$39
Montelukast Sodium11$33

Paid to pharmacies, not to this prescriber.

Other ophthalmic plastic and reconstructive surgery in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →